Natus Medical, Inc.

Medical technology company Avanos Medical is slated for acquisition by private equity-backed American Industrial Partners in a whopping $1.272 billion all-cash deal. Through the agreement, Avanos stockholders will receive $25 per share in cash for each share of common stock they own. This per-share cost represents an estimated 72.1% of the company’s stock price at market close on April 13, and an 82.8% premium for the company’s 30-day volume-weighted average share price. “Our agreement with AIP is a milestone for Avanos that reflects the strong momentum across the business. After careful consideration alongside our independent advisors, we are confident this agreement with AIP represents the right path forward for Avanos and its stockholders,” Gary Blackford, Avanos Board chair, said in a prepared statement. “The Board believes this transaction will maximize value for stockholders, create exciting new opportunities for employees, and best position Avanos for long‑term growth and success.” Board unanimously approves $1.272 billion transaction This acquisition was approved unanimously by Avanos' Board of Directors, and it will close in the second half of 2026. Following the transaction, Avanos will become a private company, and will no longer be on the New York Stock Exchange. The company will remain headquartered in Alpharetta, Georgia, a state that has seen a recent uptick in medical device deals . Unanimous approval contrasts with recent board struggles Avanos’ key focuses include its Specialty Nutrition Systems and Pain Management & Recovery franchises. This unanimous board approval marks a major success for Avanos, as several other major medical device companies have struggled to obtain board approvals for large scale acquisitions in recent months. Deals involving companies Teleflex Medical and STAAR Surgical have been marred by indecisive board votes . Private equity continues medtech acquisition spree Despite some board approval struggles, private equity has still managed to assert itself in the medical device space in recent years. In February, news leaked that Johnson & Johnson could be shedding DePuy Synthes, as several large private equity firms are said to be considering teaming up to potentially buy out the unit. In December, Teleflex sold to private equity for $1.5 billion, as did Zimvie , Surmodics , and Becton, Dickinson and Company . Medtech M&A surges A report from JP Morgan, in partnership with Dealforma, showed that M&A was thriving in 2025. Medtech IPO and M&A activity in Q3 handily surpassed full-year numbers in 2024, according to the report, signaling a high amount of interest in the space. Medtech M&A activity saw a huge uptick in Q3, with 65 transactions, the most active quarter since 2022. Those transactions totaled $21.7 billion in upfront cash and equity, the second-highest quarterly value over the same period. Avanos joins growing list of companies choosing private ownership Avanos will join a list of other key medtech companies that ditched Wall Street for private ownership, including Agiliti, Cordis, LifeScan, Natus Medical, and Vapotherm. MD+DI is set to host an exclusive webinar in collaboration with L.E.K. Consulting and sponsored by Epicor that will dive deeper into this topic.

Keriton, a market leader in innovative cloud-based software that streamlines breast milk and formula management and supports safe feeding practices, announced today that it has been acquired by Natus Sensory, a global leader in sensory and newborn care solutions. Keriton will become part of Natus Sensory’s Newborn Care portfolio, with a continued focus on innovation, clinical collaboration, and customer support. “Joining Natus Sensory marks an exciting next chapter for Keriton, accelerating adoption of our mission critical platform,” said Adam Dakin, CEO of Keriton. “We share an unwavering commitment to improving care for newborns and supporting the clinicians and families who care for them. Natus’ global presence and resources will further enhance our ability to continue providing best in class technology and support for our patients and clinical partners.” “Keriton is a strong strategic and cultural fit for Natus Sensory,” says Peter Reimer, CEO of Natus Sensory. “Their proven impact on feeding safety and focus on supporting clinical teams in the NICU and pediatric care settings aligns directly with our mission to shape the future of newborn care, where every baby has the best start in life through trusted solutions and clinical expertise. This acquisition strengthens our Newborn Care portfolio and deepens our role as a long-term partner to hospitals and care teams.” The integration of Keriton’s solution with Natus Sensory’s extensive portfolio including hearing screening and vision screening devices, jaundice phototherapy systems, NicView® video monitoring, and Neometrics® case management and reporting software and services, will enable hospitals and clinicians to access a more unified ecosystem for newborn care. Keriton is a Philadelphia based technology company focused on improving neonatal and pediatric feeding management through cloud-based software solutions. Its platform supports safer feeding practices, clinical efficiency, and family engagement across NICUs and pediatric care settings. Keriton investors include BioAdvance Capital, Dreamit Ventures, Ben Franklin Technology Partners, and the Broad Street Angels. Natus Sensory is a global leader in solutions for assessing, fitting and screening in the areas of hearing, balance, vision and newborn care, including hearing screening and vision screening devices, jaundice phototherapy systems, NicView® video monitoring, and Neometrics® case management and reporting software and services - making a meaningful difference in patient care. With a legacy of groundbreaking innovation, we are committed to improving outcomes for patients and supporting the daily work of healthcare professionals. At the core of our innovation is a dedication to listening to clinicians, ensuring every product addresses real-world challenges. Our solutions are known for their ease of use, reliability, and safety. Beyond products, Natus Sensory offers comprehensive training and education - empowering clinicians with the knowledge and support they need to deliver exceptional care. Natus Sensory is an ARCHIMED company since 2022.

Dubbed Intellidrop, BrainSpace\'s system is capable of continuous brain pressure monitoring and precision brain fluid drainage.\n BrainSpace, a medtech focused on neurological injuries and illnesses, received 501(k) clearance from the FDA for its brain fluid management system designed to aid medical staff in providing improved patient care.Dubbed Intellidrop, the system is capable of continuous brain pressure monitoring and precision brain fluid drainage, allowing clinicians to set and measure a patient’s target pressure or volume, the company said in a Jan. 2 press release.The FDA clearance is indicated for external drainage of cerebrospinal fluid (CSF) and/or monitoring of CSF drainage and intracranial pressure for ventricular or lumbar use.BrainSpace’s system can generate key data to train physical artificial intelligence models. The technology, the company said, has the potential to boost patient benefits “across the spectrum of neuro disease at every age.” “We\'ve heard from hundreds of ICU nurses that automating external CSF clearance is going to be a huge relief for nurses and a better experience for patients with traumatic brain injury, stroke, skull base tumor surgeries, neurodegenerative conditions like normal pressure hydrocephalus and more,” Caitlin Morse, chief executive and co-founder of BrainSpace, said in a statement. “That hope can now become a reality in hospitals around the U.S. with Intellidrop FDA cleared.”Back in 2022, fellow neurology-focused device maker Natus Medical, which debuted on the Nasdaq in 2001, agreed to be taken private in a $1.2 billion deal by private equity firm ArchiMed Group. The following year, Wisconsin-based Natus closed a deal to acquire Italy-based Micromed for an undisclosed amount, expanding its portfolio of neurodiagnostic and neuromonitoring products.